Navigation Links
Medco Announces Research Collaboration with FDA Focused on Personalized Medicine
Date:8/18/2008

Study to report findings on how genes impact efficacy of many commonly used

prescription medications

FRANKLIN LAKES, N.J., Aug. 18 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. (NYSE: MHS), the nation's leading pharmacy benefit manager, announced it and the Food and Drug Administration (FDA) have entered into a research partnership to study genetic testing and the impact of genetics on the efficacy of prescription drugs. The announcement adds credence to the emerging science of personalized medicine and will expand the body of evidence for the consideration of personal genetics in how doctors prescribe drugs.

Under the partnership, Medco and the FDA will jointly develop research projects, programs and strategies in the area of pharmacogenomics, collectively aimed at improving patient health and quality in the delivery of care. Pharmacogenomics is the science of capturing a patient's genetic information to help predict how a person is likely to respond to a wide variety of drugs, including commonly used prescriptions such as pain relievers, anticoagulants, and cancer drugs. This information has a bearing on what drug is selected and may help optimize doses for particular drugs. Commercial tests are currently available to identify the appropriateness of specific drug treatments based upon a patient's genetic profile.

"An increasing number of drugs are including genetic information in their labels and we're finding out how genes affect some drugs that have been widely used for generations," said Medco's Chief Medical Officer Dr. Robert Epstein. "Studying this field can advance pharmacy care to remove some of the trial and error in how medications are prescribed."

Research Partnership

The research agreement extends to Aug. 31, 2010, during which time Medco will deliver a series of reports to the FDA about pharmacogenomic testing. The topics to be studied will address the safety of prescription drugs, physician participation in pharmacogenomics testing, the usefulness of the tests in prescribing, and quantifying prescription information about drugs that have genetic information in their labels. Medco's reports will be derived from clinical settings, including one that will examine whether physicians are willing to change the dose of a prescription based on a genetic test result. Medco's database of pharmacy claims will supply a large portion of the data to be used in the reports for the FDA.

"Medco's partnership with the FDA should help establish gene testing as a tool to help lower health care costs and improve the quality of care," Epstein said. "This will come from reducing waste from treatments that do not work and also from helping prevent unnecessary hospitalizations from incorrect dosages or other adverse drug events."

Medco plans on submitting portions of the research from this partnership to peer-reviewed journals for publication with an eye on building the body of evidence supporting the value of these tests.

Medco has existing research collaborations with Mayo Clinic studying genetic consideration in the use of warfarin, and with LabCorp regarding breast cancer patients using tamoxifen. Completion of the tamoxifen study is expected this year and the warfarin study is anticipated next year. The company anticipates additional development partnerships with private companies, academic institutions and other health care entities.

Pharmacogenomics revolution

Unique differences in an individual's genes can cause variations in how many prescription drugs are metabolized in the body. These differences affect the speed of which a patient metabolizes medication -- affecting safety or efficacy from too high or low of a dose. Such a situation can be dangerous or potentially deadly in the case of common medications like warfarin or codeine. Approximately 30 percent of all medications are metabolized by one enzyme (CYP2D6). This opens up a far reaching range of genetic tests that could be used to determine how people will respond to a wide range of medications, including antidepressants, pain relievers, heartburn treatments, and antihistamines.

About Medco

Medco Health Solutions, Inc. (NYSE: MHS) is the nation's leading pharmacy benefit manager based on its 2007 total net revenues of more than $44 billion. Medco's prescription drug benefit programs, covering approximately one-in-five Americans, are designed to drive down the cost of pharmacy health care for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by the Medicare Part D Prescription Drug Program and those served by its specialty pharmacy segment, Accredo Health Group. Medco, the world's most advanced pharmacy(TM), is positioned to serve the unique needs of patients with chronic and complex conditions through its Medco Therapeutic Resource Centers(R), including its enhanced diabetes pharmacy care practice through the Liberty acquisition. Medco is the highest-ranked independent pharmacy benefit manager on the 2008 Fortune 100 list. On the Net: http://www.medco.com.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Medco Health Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
2. Medco Unveils Three New Medicare Prescription Drug Plan Options for 2008 to Provide Seniors More Choice, Better Value and Specialist Pharmacists
3. Medco Announces Date for Third-Quarter 2007 Financial Results
4. Six Olympic Legends Battling Chronic Diseases Lead Revolution in Advancing Pharmacy Care as Medco Launches the Tour of Champions
5. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
6. Medco to Build Worlds Largest, Most Advanced Automated Pharmacy in Central Indiana
7. Medco Elects Myrtle Potter, William Roper to Board of Directors
8. Medco CEO to Present at the Merrill Lynch & Co., Inc. 2007 Health Services Investor Conference
9. Medco Announces Two-For-One Stock Split
10. URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards
11. MedcomSoft appoints former U.S. presidential health advisor, James Haveman, to health Care advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... were three leading bottled water brand owners that topped the list as a result ... and optimize conversion. The premier brand was Tibet 5100, a top notch water company ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing list ... seven other locations throughout the Southeast, from Orlando to Huntsville and in between. ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are ... patients. Research shows that the Goal Attainment Scale (GAS) captures 20% more change ... and learn more about the Goal Attainment Scale, Education Resources Inc. is offering ...
(Date:2/10/2016)... ... 10, 2016 , ... IDEX Health & Science, LLC announces ... (PLS) columns combine the strength of traditional stainless steel with the chemical inertness ... while operating at ultra-high pressures of 20,000 psi. The higher operating pressures allow ...
(Date:2/10/2016)... ... 10, 2016 , ... Anxiety of older Americans over steep cost increases of ... a decade ago, according to The Senior Citizens League (TSCL). Since ... coping with rapidly rising costs. “The implications are chilling, particularly for people with ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... ANGELES , Feb. 10, 2016  Oxis International ... cancer drug, OXS-1550, was described as a "clinical trial ... the drug went into complete cancer remission. ... University of Minnesota Masonic Cancer Center. --> ... University of Minnesota Masonic Cancer Center. --> ...
(Date:2/10/2016)... , Feb. 10, 2016  LexisNexis® Risk Solutions, ... today announced the launch of LexisNexis Provider ... that helps improve and optimize the quality and ... performance using severity-adjusted scores. By measuring provider performance ... solution to deliver better outcomes, improve the patient ...
(Date:2/10/2016)... Israel , February 10, 2016 /PRNewswire/ ... leader in the field of cartilage repair, announces the ... 5, 2016. The $15 million investment was led by ... pharmaceutical manufacturer, and was joined by existing Regentis investors ... and both the Technion Research & Development Foundation and ...
Breaking Medicine Technology: